Hospira Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOSPIRA, and when can generic versions of HOSPIRA drugs launch?
HOSPIRA has five hundred and eighteen approved drugs.
There are nine US patents protecting HOSPIRA drugs. There are seven tentative approvals on HOSPIRA drugs.
There are seventy patent family members on HOSPIRA drugs in thirty-eight countries and four hundred and twenty-two supplementary protection certificates in sixteen countries.
Summary for Hospira
| International Patents: | 70 |
| US Patents: | 9 |
| Tradenames: | 333 |
| Ingredients: | 210 |
| NDAs: | 518 |
| Patent Litigation for Hospira: | See patent lawsuits for Hospira |
| PTAB Cases with Hospira as petitioner: | See PTAB cases with Hospira as petitioner |
Drugs and US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | PANCURONIUM BROMIDE | pancuronium bromide | INJECTABLE;INJECTION | 072320-001 | Jan 19, 1989 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | BIVALIRUDIN | bivalirudin | INJECTABLE;INTRAVENOUS | 090811-001 | Jul 14, 2015 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | ROPIVACAINE HYDROCHLORIDE | ropivacaine hydrochloride | SOLUTION;INJECTION | 090194-006 | Sep 23, 2014 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira | DOPAMINE HYDROCHLORIDE | dopamine hydrochloride | INJECTABLE;INJECTION | 018132-003 | Feb 4, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hospira Inc | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 065503-001 | Oct 15, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Hospira | AMPICILLIN SODIUM | ampicillin sodium | INJECTABLE;INJECTION | 202864-004 | Sep 4, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | 4,910,214*PED | ⤷ Sign Up |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | 6,716,867*PED | ⤷ Sign Up |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | 6,716,867*PED | ⤷ Sign Up |
| Hospira Inc | NIPENT | pentostatin | INJECTABLE;INJECTION | 020122-001 | Oct 11, 1991 | 3,923,785 | ⤷ Sign Up |
| Hospira | BRETYLOL | bretylium tosylate | INJECTABLE;INJECTION | 017954-001 | Approved Prior to Jan 1, 1982 | RE29618 | ⤷ Sign Up |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-003 | Mar 13, 2013 | 6,716,867*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOSPIRA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 100 mcg/mL | ➤ Subscribe | 2009-04-08 |
| ➤ Subscribe | Injection | 4 mcg/mL, 20 mL vials | ➤ Subscribe | 2015-09-30 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
| ➤ Subscribe | Injection | 4 mcg/mL, 50 mL and 100 mL vials | ➤ Subscribe | 2013-12-26 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
International Patents for Hospira Drugs
Supplementary Protection Certificates for Hospira Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1853250 | 37/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230 |
| 1115417 | 06C0022 | France | ⤷ Sign Up | PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119 |
| 1353647 | 2011C/029 | Belgium | ⤷ Sign Up | PRODUCT NAME: AZTREONAM LYSINE; AUTHORISATION NUMBER AND DATE: EU/1/09/543/001 20090923 |
| 0481754 | SPC/GB06/032 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ENTECAVIR-(2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE CYCLOPENTYL)-6H-PURIN-6-ONE AND HYDRATES THEREOF, PARTICULARLY THE MONOHYDRATE; REGISTERED: UK EU/1/06/343/001 20060626; UK EU/1/06/343/002 20060626; UK EU/1/06/343/003 20060626; UK EU/1/06/343/004 20060626; UK EU/1/06/343/005 20060626 |
| 1020461 | 300482 | Netherlands | ⤷ Sign Up | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105 |
| 2435025 | LUC00124 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
